U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018037) titled 'Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma' on June 04.
Brief Summary: The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
Study Start Date: Jan. 29
Study Type: OBSERVATIONAL
Condition:
Renal Cell Carcinoma
Recruitment Status: RECRUITING
Sponsor: Regina Elena Cancer Institute
Published by HT Digital Content Services with permission from Health Daily Digest....